Pharmacologic reversal of cortical hyperexcitability in patients with ALS

Neurology

Volumn 54, Issue 1, 2000, Pages 58-64

  Donatella Caramia, M ^a,b,c   Giuseppina Palmieri, M ^a,b   Desiato, M T ^a   Iani, C ^a   Scalise, A ^a,b   Telera, S ^a,b   Bernardi, G ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c S EUGENIO HOSPITAL   (Italy)

Author keywords

ALS; GABAergic drugs; Intracortical inhibition; Motor evoked potential; Paired transcranial magnetic stimulation

Indexed keywords

DIAZEPAM; GABAPENTIN; RILUZOLE;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BRAIN CORTEX; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; EVOKED MUSCLE RESPONSE; FEMALE; GABAERGIC SYSTEM; HUMAN; MALE; MUSCLE ATROPHY; MUSCLE WEAKNESS; NERVE CELL EXCITABILITY; NEUROPATHOLOGY; PRIORITY JOURNAL; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 0033974104     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.54.1.58     Document Type: Article

References (38)

1. Jerusalem F, Fohl C, Karitzky J, Ries F. ALS. Neurology. 1996;47(suppl 4):S218-S220.
2. Hugon J ALS therapy: targets for the future. Neurology 1996; 47(suppl 4):S251-S254.
3. Miller RG, Petajan JH, Brian WW, et al. A placebo controlled trial of recombinant human Ciliary Neurotrophic (rhCNTF) Factor in amyotrophic lateral sclerosis. Ann Neurol 1996;39: 256-260.
4. Offen D, Halevi S, Orion D, et al. Antibodies from ALS patients inhibit dopamine release mediated by L-type calcium channels. Neurology 1998;51:1100-1103.
5. Leigh PN, Meldrum BS. Excitoxicity in ALS. Neurology 1996; 47(suppl 4):S221-S227.
6. Hugon J, Lubeau M, Tabaraud F, Chazot F, Vallat JM, Dumas M. Central motor conduction in motor neuron disease. Ann Neurol 1987;22:544-546.
7. Ingram DA, Swash M. Central motor conduction is abnormal in motor neuron disease. J Neurol Neurosurg and Psychiatry 1987;50:159-166.
8. Eisen AA, Shytbel W, Murphy K, Hoirch M. Cortical magnetic stimulation in amyotrophic lateral sclerosis. Muscle Nerve 1990;13:146-151.
9. Caramia MD, Cicinelli P, Paradiso C, et al. Excitability changes of muscular responses to magnetic brain stimulation in patients with central motor disorders. Electroenceph Clin Neurophysiol 1991;81:243-250.
10. Eisen A, Pant B, Stewart H. Cortical excitability in amyotrophic lateral sclerosis: a clue to pathogenesis. Can J Neurol Sci 1993;20:11-16.
11. Desiato MT, Caramia MD. Towards a neurophysiological marker of amyotrophic lateral sclerosis as revealed by changes in cortical excitability. Electroenceph Clin Neurophysiol 1997;105:1-7.
12. Ziemann U, Winter M, Reimers CD, Reimers K, Tergau F, Paulus V. Impaired motor cortex inhibition in patients with amyotrophic lateral sclerosis. Neurology 1997;49:1292-1298.
13. Enterzari-Taher M, Eisen A, Stuart H, Nakajima M. Abnormalities of cortical inhibitory neurons in amyotrophic lateral sclerosis. Muscle Nerve 1997;20:65-71.
14. Salerno A, Georgesco M. Double magnetic stimulation of the motor cortex in amyotrophic lateral sclerosis. Electroenceph Clin Neurophysiol 1998;107:133-139.
15. Kujirai T, Caramia MD, Rothwell JC, et al. Cortico-cortical inhibition in human motor cortex. J Physiol 1993;471:501-519.
16. Caramia MD, Gigli G, Iani C, et al. Distinguishing forms of generalized epilepsy using magnetic brain stimulation. Electroenceph Clin Neurophysiol 1996;98:14-19.
17. Bensimon G, Lancomblez L, Meininger V, for the ALS/ Riluzole study group. A controlled trial of riluzole in amyotrophic lateral sclerosis. New Engl J Med 1994;330:585-591.
18. Welty DF, Schielke GP, Rothstein JD. Potential treatment of amyotrophic lateral sclerosis with gabapentin: a hypothesis. Ann Pharmacother 1995;29:1164-1167.
19. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994; 124(suppl):96-107.
20. Appel V, Stewart SS, Smith G, Appel SH. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol 1987;22:328-333.
21. Palmieri MG, Iani C, Scalise A, et al. The effect of benzodiazepines and flumazenil on motor cortical excitability on the human brain. Brain Res 1999;815:192-199.
22. Bellantuono C, Reggi V, Tognoni G, Garattini S. Benzodiazepines. Clinical pharmacology and therapeutic use. Drugs 1980;19:192-219.
23. Rossini PM, Desiato MT, Lavaroni F, Caramia MD. Brain excitability and electroencephalographic activation: non-invasive evaluation in healthy humans via transcranial magnetic stimulation. Brain Res 1991;567:111-119.
24. Revick DA, Leidy NK. Questionnaire scaling: models and issues. In: Staquet MJ, Hays RD, Fayers PM, eds. Quality of life assessment in clinical trials. UK: Oxford University Press, 1998:157-168.
25. Brasil-Neto JP, Cohen LG, Panizza M, et al. Optimal focal transcranial magnetic activation of the human motor cortex: effects of coil orientation, shape of the induced current pulse and stimulus intensity. J Clin Neurophysiol 1992;9:132-136.
26. Werhahn KJ, Fong JKY, Meyer B-U, et al. The effect of magnetic coil orientation on the latency of surface EMG and single motor unit responses in the first interosseous muscle. Electroenceph Clin Neurophysiol 1994;93:138-214.
27. Caramia MD, Pardal AM, Zarola F, Rossini PM. Electric versus magnetic transcranial stimulation of the brain in healthy humans: a comparative study of the central motor tracts conductivity and excitability. Brain Res 1989;479:98-104.
28. Mills KR, Nithi KA. Corticomotor threshold to magnetic stimulation: normal values and repeatability. Muscle Nerve 1999; 20:570-576.
29. Rossini PM, Barker AT, Berardelli A, et al. Non-invasive electrical and magnetic stimulation of the brain, spinal cord and roots: basic principles and procedures for routine clinical applications. Report of an IFCN committee. Electroenceph Clin Neurophysiol 1994;91:79-92.
30. Zar JH. Biostatistical analysis. Englewood Cliffs, NJ: Prentice-Hall, 1974.
31. Ziemann U, Lonneker S, Steinhoff BJ, Paulus W. Effects of antiepileptic drugs on motor cortex excitability in humans: a transcranial magnetic stimulation study. Ann Neurol 1996;40: 367-378.
32. Ziemann U, Lonnecker S, Steinhoff BJ, Paulus W. The effect of lorazepam on the motor cortical excitability in man. Exp Brain Res 1996;109:127-135.
33. Romano JG. Reduction of fasciculations in patients with amyotrophic lateral sclerosis with the use of gabapentin. Arch Neurol 1996;53:716.
34. Ridding MC, Inzelberg R, Rothwell JC. Changes in the excitability of motor cortical circuitry in patients with Parkinson's disease. Ann Neurol 1995;37:181-188.
35. Macdonald RL, Greenfield LJ. Mechanisms of new antiepileptic drugs. Current Opinion Neurol 1997;10:121-128.
36. Taylor CP, Gee NS, Su Tz, et al. A summary mechanistic hypothesis of gabapentin pharmacology. Epilepsy Res 1998; 29:233-249.
37. Doble A. The pharmacology and mechanism of action of riluzole. Neurology 1996;47(suppl 49):S233-S241.
38. Gurney ME, Timothy JF, Himes CS, Hall ED. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology 1998;50:62-66.